GLP-1 medications in Ireland: what TikTok gets right and wrong

What did @ozempicirelandmds actually say?

Nothing medically relevant, as far as we can tell. The transcript from this video is not a health claim at all. It reads like song lyrics: "Once better than twice shy I keep my distance but you still catch my eye" and continues in that vein for several lines. There is no mention of semaglutide, tirzepatide, GLP-1 receptors, weight loss, dosing, or any clinical topic.

This could mean the automatic transcription failed, the audio was a background track, the creator used a trending sound without speaking over it, or the video was misclassified. Whatever the reason, we cannot fact-check medical claims that were not made. What we can do is use this space to address what someone visiting a page called @ozempicirelandmds might actually want to know.

Does the science back this up?

There is no claim here to evaluate against the science. But given the account name and category, the relevant science worth knowing is substantial. GLP-1 receptor agonists have one of the stronger evidence bases in recent obesity medicine.

Semaglutide 2.4mg weekly (Wegovy) produced mean weight loss of around 14.9% over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), which was a randomized controlled trial in adults with obesity or overweight plus a weight-related condition. Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, showed even larger effects in the SURMOUNT-1 trial, with up to 22.5% mean body weight reduction at the highest dose (Jastreboff et al., 2022, New England Journal of Medicine). These are not trivial numbers. They represent a genuine shift in what pharmacological weight management can achieve.

That said, durability matters. Weight tends to return after stopping these medications, as shown in the STEP 4 withdrawal data (Rubino et al., 2021, JAMA).

What did they get wrong (or right)?

They did not get anything wrong or right medically in this video, because the transcript contains no medical content. Giving a pass or a failing grade here would be meaningless.

What is worth flagging, however, is a broader pattern on GLP-1 content on TikTok. A 2023 analysis of health claims on social media found that accounts using brand names like Ozempic in their handles or captions frequently mixed personal testimonials with implied clinical guidance, without disclosing whether the creator held a medical license or was affiliated with a prescribing service. Viewers tend to weight that content as authoritative regardless of actual credentials.

If @ozempicirelandmds is a legitimate Irish medical practice or telehealth service, future videos should clearly state that content is educational, not individualized medical advice, and should link to actual prescribing information. If the account is not run by licensed clinicians, the name itself is arguably misleading.

What should you actually know?

If you landed here looking for real information about GLP-1 medications, here is what the evidence actually supports. These drugs work by mimicking hormones that regulate appetite and glucose metabolism. They slow gastric emptying, reduce hunger signaling, and in the case of tirzepatide, also activate GIP receptors, which appears to amplify the weight loss effect.

Common side effects include nausea, vomiting, and constipation, particularly during dose escalation. Rare but serious risks include pancreatitis and, in rodent studies, thyroid C-cell tumors, which is why these drugs carry a boxed warning for patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Compounded versions of semaglutide have circulated widely, particularly during shortage periods. Compounded drugs are not FDA-approved and have not been shown to be equivalent to brand-name formulations in terms of sterility, potency consistency, or inactive ingredient safety. Anyone considering a compounded GLP-1 should understand that distinction clearly before starting.

A qualified clinician, ideally one with experience in obesity medicine or endocrinology, should be involved in any prescribing decision. No TikTok video, including this one, substitutes for that.